Back to Search
Start Over
Osimertinib-induced interstitial lung disease in a patient with non-small cell lung cancer pretreated with nivolumab: A case report.
- Source :
- Molecular & Clinical Oncology; 2017, Vol. 7 Issue 3, p383-385, 3p
- Publication Year :
- 2017
-
Abstract
- Osimertinib (AZD9291) is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor approved for EGFR-T790M-positive non-small cell lung cancer. A high incidence of interstitial lung disease (ILD) during combination treatment with osimertinib and anti-programmed cell death-ligand 1 (PD-L1) inhibitor has been reported. The current study presents a case of ILD development during osimertinib treatment following nivolumab (an anti-PD-1 antibody) treatment. The 59-year-old female was diagnosed with stage IV lung adenocarcinoma harboring a deletion in exon 19 of the EGFR gene. Following nivolumab as a sixth-line treatment, an EGFR-T790M-encoding mutation in EGFR exon 20 was identified by re-biopsy. Osimertinib was therefore initiated as a seventh-line treatment. A partial response was subsequently noted; however, 63 days after initiation of the treatment the patient presented with dyspnea with decreased oxygenation in the absence of fever and sputum. A computed tomography scan revealed the emergence of ground-glass opacities with bronchiectasis in both lungs, and a diagnosis of ILD due to osimertinib was made. Following steroid pulse therapy with discontinuation of osimertinib, the patient's chest findings and respiratory condition improved. Therefore, it is considered that anti-PD-1 therapies may be associated with a risk of ILD during subsequent osimertinib treatment. [ABSTRACT FROM AUTHOR]
- Subjects :
- LUNG diseases
NON-small-cell lung carcinoma
OSIMERTINIB
Subjects
Details
- Language :
- English
- ISSN :
- 20499450
- Volume :
- 7
- Issue :
- 3
- Database :
- Complementary Index
- Journal :
- Molecular & Clinical Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 124425322
- Full Text :
- https://doi.org/10.3892/mco.2017.1349